|
|
|
| Correlation Analysis of Serum IL-32 sRAGE and NLR with Multiple Myeloma Complicated with Renal Injury |
| JIANG Ming, XU Juan, DING Linlin, et al |
| Rugao People's Hospital, Jiangsu Rugao 226500, China |
|
|
|
|
Abstract Objective: To investigate the correlation between serum interleukin-32(IL-32), soluble advanced glycation end-product receptor (sRAGE) and neutrophil/lymphocyte ratio (NLR) and multiple myeloma complicated with kidney injury. Methods: A total of 82 MM patients diagnosed and treated in Rugao People's Hospital from June 2020 to June 2022 were selected as the observation group, and were divided into renal injury group (n=27) and non-renal injury group (n=55) according to renal function, and 41 healthy physical examination patients were selected as the healthy control group during the same period. IL-32, sRAGE and NLR levels were compared. Binary Logistic regression was used to analyze the effects of IL-32, sRAGE and NLR on kidney injury in MM patients. ROC curve model was used to analyze the AUC value, sensitivity and specificity of IL-32, sRAGE and NLR in predicting kidney injury in MM patients. Results: IL-32 and NLR in observation group were higher than those in control group, while sRAGE was lower than those in control group (P<0.05). IL-32 and NLR in renal injury group were higher than those in control group, while sRAGE was lower (P<0.05). Logistic regression model analysis showed that increased IL-32, increased NLR and decreased sRAGE levels were risk factors for kidney injury in multiple myeloma patients (P<0.05). ROC curve analysis showed that the AUC values of serum IL-32, sRAGE and NLR in predicting kidney injury in multiple myeloma patients were 0.761, 0.765 and 0.802, P<0.05. Conclusion: Serum IL-32, sRAGE, and NLR expression levels increased with kidney injury in MM patients.
|
|
|
|
|
|
[1] 范泽文,褚娜利,张靖宇,等.多发性骨髓瘤患者血液分离结果的演变特征及临床意义[J].中国实验血液学杂志,2022,30(2):449-454.
[2] Qu J,Hou Y,Chen Q,et al.RNA demethylase ALKBH5 promotes tumorigenesis in multiple myeloma via TRAF1-mediated activation of NF-κB and MAPK signaling pathways[J].Oncogene,2022,41(3):400-413.
[3] 中国医师协会血液科医师分会,中华医学会血液学分会.中国多发性骨髓瘤诊治指南(2022年修订)[J].中华内科杂志,2022,61(5):480-487.
[4] Terpos E,Dimopoulos MA,Boccadoro M,et al.Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab:Patient-reported outcomes from the APOLLO trial[J].Am Hematol,2022,97(4):481-490.
[5] 柴海霞,刘静梅,王会军,等.血清可溶性血栓调节蛋白及乳脂球表皮生长因子8水平与感染性休克合并急性肾损伤患者预后的相关性分析[J].中国医药,2022,17(3):425-428.
[6] 费晓莉,章帆,张开基,等.IL-32,Cys-C和β2-MG在多发性骨髓瘤患者外周血中的表达[J].西南大学学报(自然科学版),2021,43(3):30-35.
[7] 李平,王东,代小雨,等.NLR和PLR以及CAR联合血清胱抑素C对急性胰腺炎合并急性肾损伤的预测价值[J].临床急诊杂志,2021,22(9):592-596,602.
[8] 庄妮拉,詹文丽,莫泰金,等.血清IL-9、IL-18及IL-32水平对多发性骨髓瘤患者肾损伤的诊断价值[J].临床肾脏病杂志,2021,21(7):556-561.
[9] 黄娟娟,卓芬,带成斐,等.血清IL-6、IL-8及IL-32水平对多发性骨髓瘤患者肾损伤的诊断价值[J].国际泌尿系统杂志,2022,42(6):1097-1100.
[10] Butcher L,Carnicero JA,Peres K,et al.Higher sRAGE levels predict mortality in frail older adults with cardiovascular disease[J].Gerontology,2021,67(2):202-210. |
|
|
|
2023, Vol. 29 
